Abstracts Archive - Page 1775 of 2607 - ACR Meeting Abstracts

Abstract Number: 2644 • 2016 ACR/ARHP Annual Meeting
Patient Survey Regarding Generic and Bio-Similar Drugs
Tsukasa Matsubara¹, Tamami Yoshitama¹, Kou Katayama¹, Shigehito Kiyokawa², Nobumasa Miyake², Motohiro Oribe², Akira Sagawa² and Keiko Funahashi³, ¹Japanese clinician biologics research group, Kobe, Hyogo, Japan, ²Japanese clinician biologics research group, Kobe, Japan, ³Clinical Research, Matsubara Mayflower Hospital, Kato, Japan
Background/Purpose: In Japan the market share for generic drugs is 50%, lower than that in Western nations. This is partially due to Japan’s insurance system,…
Abstract Number: 2645 • 2016 ACR/ARHP Annual Meeting
Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials
Salvador R. Garcia¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Department of Medicine. Section of Allergy Immunology and Rheumatology., Department of Medicine, Section of Allergy Immunology and Rheumatology, Baylor College of Medicine, Houston, Texas, USA., Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: The objective of this systematic review was to evaluate the clinical evidence on the efficacy of different drug regimens for the treatment of early…
Abstract Number: 2646 • 2016 ACR/ARHP Annual Meeting
Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis
Tzu-Chieh Lin¹, Mirhelen Mendes De Abreu², Sara K. Tedeschi¹, Kazuki Yoshida³ and Daniel H. Solomon², ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Department of Epidemiology, Harvard School of Public Health, Boston, MA
Background/Purpose: There is limited information for the rate of hepatitis B reactivation in inflammatory arthritis patients. We conducted a systematic review and meta-analysis, assessing hepatitis…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 2648 • 2016 ACR/ARHP Annual Meeting
Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Bogdan Ion Gavrila¹, Claudia Ciofu², Victor Stoica³, Cornel Ursaciuc⁴, Dan Ciotaru⁴, Mihaela Surcel⁵, Adriana Munteanu⁴ and Eugenia Panaitescu⁶, ¹Internal Medicine and Rheumatology, Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ²Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ³Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁴INCD ,,Victor Babeș’’, Bucharest, Romania, Bucharest, Romania, ⁵INCD ,,Victor Babeș’’, Bucharest, Romania, bucharest, Romania, ⁶Carol Davila University of Medicine and Pharmacy ,Medical Informatics and Biostatistics, Bucharest, Romania
Background/Purpose: discovery of biomarkers that can identify pretreatment patients who will respond to biologic DMARDs therapy is one of the major interests in RA. We…
Abstract Number: 2649 • 2016 ACR/ARHP Annual Meeting
Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey
Fouad Fayad¹, Nelly Ziade², Georges Merheb^3,4, Said Attoui⁵, Alla Aiko⁶, Kamel Mroue⁵ and Abdel Fattah Masri⁷, ¹Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Holly Spirit University, Kaslik, Lebanon, ⁵Hammoud University Medical Center, Saida, Lebanon, ⁶Saint Georges Hospital, Beirut, Lebanon, ⁷American University of Beirut Medical Center, Beirut, Lebanon
Background/Purpose: Treatment options in rheumatoid arthritis (RA) have expanded significantly over recent years, and several agents are now available for oral, subcutaneous (SC) or intravenous…
Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting
Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Stefan Florentinus³, Su Chen³, Jessica L. Suboticki³ and Josef S. Smolen⁴, ¹Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…
Abstract Number: 2652 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis
Manon Redondin¹, B Combe², Cécile Gaujoux-Viala³, Jacques Morel⁴ and Cédric Lukas⁵, ¹CHU Lapeyronie, University of Montpellier, France, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³CHU Nîmes, University of Montpellier, France, ⁴Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have a lower life expectancy than general population. The impact of RA treatments on global mortality is not…
Abstract Number: 2653 • 2016 ACR/ARHP Annual Meeting
Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA
GR Burmester¹, MA Michaels², D Close³, A Godwood³, K Middleton³, P Miranda⁴, J Vencovský⁵, JM Kremer⁶, IB McInnes⁷, M Albulescu^³ and Michael Weinblatt⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²MedImmune, Gaithersburg, MD, ³MedImmune, Cambridge, United Kingdom, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Charles University, Prague, Czech Republic, ⁶The Albany Medical College, Albany, NY, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Brigham and Women’s Hospital, Boston, MA
Background/Purpose: RA is associated with significant pulmonary comorbidity and declines in lung function over time; but longitudinal assessment of pulmonary abnormalities in the context of…
Abstract Number: 2654 • 2016 ACR/ARHP Annual Meeting
Association Between Rheumatoid Factor Positivity and Effects of Treatment with a First Biologic Agent in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima³ and Naoki Ishiguro⁴, ¹orthopedic surgery, Sakashita Hospital, Nakatsugawa, Japan, ²Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Nagoya University, Nagoya, Japan
Background/Purpose: The presence of rheumatoid factor (RF) plays an important role in the diagnosis of rheumatoid arthritis (RA). However, whether RF positivity is related to…
Abstract Number: 2655 • 2016 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Toshiyuki Watanabe¹, Shinji Fukaya² and Kazumasa Akikawa², ¹3rd Department of Internal Medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan, ²3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is one of the most serious complications in rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 2657 • 2016 ACR/ARHP Annual Meeting
Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity
Dong Jin Go^1,2, Kichul Shin³, Han Joo Baek⁴, Seong-Wook Kang⁵, Young Mo Kang⁶, Jae-Bum Jun⁷, Yun Jong Lee⁸, Sung-Hwan Park⁹ and Yeong Wook Song^10,11, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ⁸Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ¹¹Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea
Background/Purpose: Although nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving joint pain in rheumatoid arthritis (RA) patients, long-term use of NSAIDs can cause adverse effects.…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].